Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21994806 | 0.99 | CTSK (0.47) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL21994809 | 0.99 | CTSK (0.47) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL21571117 | 0.96 | HDAC4 (0.46) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL20166296 | 0.96 | HDAC4 (0.46) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL27586355 | 0.96 | HDAC4 (0.46) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL21409067 | 0.92 | CTSK (0.44) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL21409064 | 0.92 | CTSK (0.44) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL30191484 | 0.88 | CTSK (0.47) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL21994419 | 0.87 | CTSK (0.44) | CTSKCTSSALDH1A1TSHRMEN1 | |
| SCHEMBL21994417 | 0.87 | CTSK (0.44) | CTSKCTSSALDH1A1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493402-B2 | Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| EP-1366018-B1 | OMEGA-AMINOALKYLAMIDES OF (R)-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPÉ FARMACEUTICI S P A (IT) | 2016-07-06 | — | — | EP | disclosed |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | Dompé S.p.A. (IT) | 2013-03-28 | — | — | US | disclosed |
| US-8288368-B2 | inhibitors of the C5a induced chemotaxis; psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion | DOMPÉ PHA.R.MA S.P.A. (IT) | 2012-10-16 | — | — | US | disclosed |
| US-8133864-B2 | PAR-2 agonist | KOWA COMPANY, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-1864994-B1 | PAR-2 AGONIST | KOWA CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20090215703-A1 | PAR-2 Agonist | KOWA COMPANY, LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1864994-A1 | PAR-2 AGONIST | Kowa Company, Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPE S.P A. (IT) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | C5AR2, C3AR1, C5AR1 | CTSK 2645/4885HDAC4 4511/4885HDAC1 3544/4885 |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | C5AR2, C3AR1, C5AR1 | CTSK 2872/4885HDAC4 3844/4885HDAC1 3219/4885 |
| US-20090215703-A1 | PAR-2 Agonist | FPR2, F2RL1, FPR3 | CTSK 2813/4885HDAC4 1751/4885HDAC1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.